View Discovery

Clinical Pipeline

Learn more about our pipeline

Trials for Market Approval Download PPT

Pre-Clinical (GLP)

Institute of Materia Medica, CAMS & PUMC
GlaxoSmithKline, Bill & Melinda Gates Foundation
Microbiotix, Inc.

Phase 1

TB Alliance, University of Auckland, Merck & Co., Inc.
GlaxoSmithKline, TB Drug Accelerator, Bill & Melinda Gates Foundation
TB Alliance, Institute of Materia Medica
iM4TB - Innovative Medicines for Tuberculosis, Bill & Melinda Gates Foundation
Institute of Materia Medica, CAMS & PUMC
TB Alliance, Bill & Melinda Gates Medical Research Institute, Foundation for Neglected Disease Research

Phase 2

University of Munich, Hans-Knöll Institute, Jena, German Center for Infection Research (DZIF), European and Developing Countries Clinical Trials Partnership (EDCTP), Radboud University
Qurient Co., Ltd, Qurient Co. Ltd. / LLC "Infectex", a portfolio firm of Maxwell Biotech Venture Fund
Nearmedic Plus LLC
Sequella, Inc, TB Alliance
Otsuka Pharmaceutical Development & Commercialization, Inc.
Sequella, Inc
NIAID, NIH, DHHS, Bill & Melinda Gates Foundation, EDCTP
CDC TBTC, NIAID, NIH, DHHS, Boston University